Madrigal Pharmaceuticals Inc (MDGL.OQ)
June 13 The following bids, mergers, acquisitions and disposals were reported by 2020 GMT on Wednesday:
Madrigal Pharmaceuticals Inc is exploring a sale, Bloomberg reported on Wednesday, citing people familiar with the matter, nearly three weeks after the company reported mid-stage data from its drug to treat non-alcoholic steatohepatitis or NASH.
June 13 Madrigal Pharmaceuticals Inc is exploring a sale, Bloomberg reported https://www.bloomberg.com/news/articles/2018-06-13/madrigal-pharma-is-said-to-explore-sale-amid-takeover-interest on Wednesday, citing people familiar with the matter, nearly three weeks after the company reported mid-stage data from its drug to treat non-alcoholic steatohepatitis or NASH.
Madrigal Pharmaceuticals Inc's shares more than doubled after mid-stage trial data showed its lead drug reduced liver fat in patients with fatty liver disease, placing it ahead of larger rivals to tap into a potential market worth $30 billion.
May 31 Madrigal Pharmaceuticals Inc said on Thursday its lead experimental drug achieved the main goal of reducing liver fat in patients with a type of liver disease in a mid-stage study, sending its shares surging 40 percent in premarket trading.
May 31 Madrigal Pharmaceuticals Inc said on Thursday a mid-stage trial testing its lead experimental treatment for a liver disease achieved the main goal of reducing liver fat.
* MADRIGAL PHARMACEUTICALS REPORTS 2018 FIRST QUARTER FINANCIAL RESULTS AND REVIEWS KEY CLINICAL ACHIEVEMENTS
* MADRIGAL PHARMACEUTICALS REPORTS 2017 FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS, REVIEWS KEY CORPORATE ACHIEVEMENTS AND PROVIDES CLINICAL UPDATE ON MGL-3196
BRIEF-Madrigal's MGL-3196 Achieves Primary Endpoint In Patients With Heterozygous Familial Hypercholesterolemia
* MADRIGAL'S MGL-3196 ACHIEVES PRIMARY ENDPOINT IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH)
|Otsuka Holdings Co Ltd (4578.T)||¥5,170||--|
|DAIICHI SANKYO COMPANY, LIMITED (4568.T)||¥4,577||--|
|Kyowa Hakko Kirin Co Ltd (4151.T)||¥2,243||--|
|Johnson & Johnson (JNJ.N)||$129.11||+4.42|
|Abbott Laboratories (ABT.N)||$62.80||+1.02|
|Amgen, Inc. (AMGN.OQ)||$193.92||-0.96|
|Wyeth Limited (WLED.NS)||Rs1,333.85||--|
|Celgene Corporation (CELG.OQ)||$85.85||+0.62|
|Seattle Genetics, Inc. (SGEN.OQ)||$67.94||-1.05|
|Endocyte, Inc. (ECYT.OQ)||$16.93||+0.43|